Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Arthritis Rheum. 2011 Nov;63(11):3274–3283. doi: 10.1002/art.30573

FIGURE 2. Anti-CXCR3 antibodies significantly reduce DA FLS production of activated MMP-1.

FIGURE 2

(A) Densitometry analyses showing that anti-CXCR3 treatment significantly reduced DA FLS production of active MMP-1 (n=3; *P=0.001; t-test; mean±S.D.). (B) Representative western blot of the above densitometries demonstrating significant reduction in the levels of active form of MMP-1 in supernatants of FLS treated with anti-CXCR3, compared with no-treatment and isotype control.